Trial Profile
Randomized Phase II Trial of Gemcitabine and Imatinib Mesylate Versus Gemcitabine Alone in Patients With Previously Treated Locally Advanced or Metastatic Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 22 Sep 2021
Price :
$35
*
At a glance
- Drugs Imatinib (Primary) ; Gemcitabine
- Indications Advanced breast cancer; Male breast cancer
- Focus Therapeutic Use
- 17 Mar 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Jun 2015 as per ClinicalTrials. gov record.
- 04 Jun 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
- 24 May 2013 Status changed from active, no longer recruiting to discontinued.